Alex Thurman Sells 625 Shares of Glaukos (NYSE:GKOS) Stock

Glaukos Corporation (NYSE:GKOS) CFO Alex Thurman sold 625 shares of the stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $99.15, for a total value of $61,968.75. Following the completion of the sale, the chief financial officer directly owned 49,249 shares of the company’s stock, valued at $4,883,038.35. The trade was a 1.25% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Glaukos Stock Performance

Shares of Glaukos stock traded down $0.96 during trading on Thursday, reaching $102.26. The company’s stock had a trading volume of 599,545 shares, compared to its average volume of 796,748. The company has a 50-day moving average price of $113.95 and a two-hundred day moving average price of $101.37. Glaukos Corporation has a fifty-two week low of $73.16 and a fifty-two week high of $130.23. The firm has a market cap of $5.94 billion, a PE ratio of -31.37 and a beta of 0.70. The company has a current ratio of 4.69, a quick ratio of 4.06 and a debt-to-equity ratio of 0.10.

Glaukos (NYSE:GKOS) last posted its quarterly earnings data on Tuesday, February 17th. The medical instruments supplier reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.06). Glaukos had a negative net margin of 36.99% and a negative return on equity of 7.00%. The business had revenue of $143.12 million during the quarter, compared to analyst estimates of $132.16 million. During the same quarter in the prior year, the firm posted ($0.40) earnings per share. The company’s revenue for the quarter was up 35.6% compared to the same quarter last year. On average, analysts forecast that Glaukos Corporation will post -1.08 EPS for the current year.

Wall Street Analysts Forecast Growth

GKOS has been the topic of a number of recent research reports. Truist Financial boosted their target price on Glaukos from $120.00 to $145.00 and gave the company a “buy” rating in a report on Thursday, December 18th. Wall Street Zen downgraded Glaukos from a “buy” rating to a “hold” rating in a report on Saturday, February 21st. William Blair upgraded shares of Glaukos to a “strong-buy” rating in a research report on Friday, January 30th. Needham & Company LLC upped their price objective on shares of Glaukos from $125.00 to $127.00 and gave the stock a “buy” rating in a research report on Wednesday, February 18th. Finally, The Goldman Sachs Group restated a “buy” rating and issued a $138.00 target price on shares of Glaukos in a research note on Friday, January 9th. One analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $133.69.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of GKOS. Fund Advisors of America Inc FL purchased a new stake in shares of Glaukos during the 4th quarter worth $219,000. Corient Private Wealth LLC increased its holdings in shares of Glaukos by 999.3% in the 4th quarter. Corient Private Wealth LLC now owns 30,978 shares of the medical instruments supplier’s stock valued at $3,498,000 after purchasing an additional 28,160 shares in the last quarter. Invesco Ltd. increased its holdings in shares of Glaukos by 28.5% in the 4th quarter. Invesco Ltd. now owns 780,267 shares of the medical instruments supplier’s stock valued at $88,100,000 after purchasing an additional 172,825 shares in the last quarter. Summit Global Investments lifted its stake in shares of Glaukos by 151.3% in the fourth quarter. Summit Global Investments now owns 7,052 shares of the medical instruments supplier’s stock valued at $796,000 after purchasing an additional 4,246 shares during the period. Finally, Mackenzie Financial Corp boosted its holdings in Glaukos by 331.8% during the fourth quarter. Mackenzie Financial Corp now owns 15,404 shares of the medical instruments supplier’s stock worth $1,756,000 after buying an additional 11,837 shares in the last quarter. Institutional investors and hedge funds own 99.04% of the company’s stock.

About Glaukos

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.